Sana's UP421 Stem Cell Transplant Shows Promise in Type 1 Diabetes

Sana’s UP421 Stem Cell Transplant Shows Promise in Type 1 Diabetes

Sana Biotechnology’s new type of stem cell transplant islet cells shows promise for a potential treatment for type 1 diabetes. The therapy, UP421 stem cell transplant enrolled patients to avoid immune rejection and produce insulin.

As Per-Ola Carlsson, M.D., study principal pnvestigator, senior physician and professor at the Clinic for Endocrinology and Diabetology at Uppsala University Hospital. “The clinical data are highly promising for patients and provide the first evidence in humans for overcoming allogeneic and autoimmune rejection with pancreatic islet cell transplantation in type 1 diabetes with no immunosuppression.”

Read the full article here!

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.